EGFR and hepatocellular carcinoma: While EGFR inhibitors such as cetuximab, gefitinib and erlotinib showed therapeutic effect by controlling HCC cell line proliferation and by reducing liver fibrogenesis in HCC animal models (20, 21), objective response rate of these drugs against HCC ranges from 6.6% to 30% (22, 23).